Study of the patient satisfaction in the self-reporting-questionnaire after the switching PPI from existing PPI to Esomeprazole in the reflux esophagitis patients

Study of the patient satisfaction in the self-reporting-questionnaire after the switching PPI from existing PPI to Esomeprazole in the reflux esophagitis patients - Study of the patient satisfaction in a self-reporting-questionnaire after the Esomeprazole switching

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010808

Enrollment

Registered

2013-05-27

Start date

2013-05-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD

Interventions

Esomeplazole 20mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who fills everything the following 1) Man or woman who is 20 years old or older at the time of getting informed consent 2) Patient whom is given existing PPI, but one of the heartburn or acid reflux symptoms remains in 3) Patient that a document informed consent by the free intention of patients was gotten on enough understanding after having received enough explanation on participating in this study

Exclusion criteria

Exclusion criteria: The patient in conflict with the following exclusion criteria is not enrolled 1) Patient with the drug allergy 2) Patient who complicated a serious heart disease, serious liver disease, renal function disorder, and malignant tumor

Design outcomes

Primary

Measure	Time frame
Assessment of patient satisfaction in a self-reporting-questionnaire	—

Secondary

Measure	Time frame
Comparison of the effect according to the background factor	—

Countries

Japan

Contacts

Public ContactMasahiko Inamori

Yokohama City University Graduate School of Medicine Gastroenterology Division

045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026